Tag Archives: Narcolepsy

Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts

Two biotechs this week topped the $100 million mark in their respective initial public offerings, both of which were able to offer more shares than planned. One, a company with nearly nine month’s-worth of revenue from a newly commercialized drug and the other, an early-clinical stage oncology drug developer, illustrate the range of biotech companies […]

Posted in National, National blog main, National top stories, Philadelphia Blog Main, Philadelphia Top stories, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , , , , , , | Comments Off on Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts

Jazz Pharma Gets FDA Nod for New Drug to Treat Narcolepsy Symptoms

[Corrected 7/23/20, 10:13 am. See below.] Jazz Pharmaceuticals has received FDA approval for a narcolepsy drug that it has developed as a lower-sodium successor to its biggest moneymaker, a treatment that was first approved in 2002 to reduce attacks of muscle weakness associated with the disease. That drug, sodium oxybate (Xyrem), was first OK’d to reduce […]

Posted in Europe, Europe blog main, Europe top stories, National blog main, National top stories, Philadelphia Blog Main, San Francisco blog main | Tagged , , , , , , , , , , , | Comments Off on Jazz Pharma Gets FDA Nod for New Drug to Treat Narcolepsy Symptoms

Concert Pharma Heads to Nasdaq, Prices IPO at $14 Per Share

What’s it worth to add a little deuterium to drugs to boost their abilities? In Wall Street’s eyes, about $14 per share. Lexington, MA-based Concert Pharmaceuticals will debut on the Nasdaq today after pricing its IPO at the top of its projected range of $14 per share. The company sold 6 million shares in the […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Concert Pharma Heads to Nasdaq, Prices IPO at $14 Per Share

Concert Pharma, Jazz Pharma Strike $120M Deal for Narcolepsy

If there was ever an occasion to play some Miles Davis around a Boston biotech company’s office, today is the day. Lexington, MA-based Concert Pharmaceuticals has the right to play it cool, or at least crack a few music jokes, after striking a collaboration with another musically inspired company—Dublin, Ireland-based Jazz Pharmaceuticals (NASDAQ: JAZZ). The […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , | Comments Off on Concert Pharma, Jazz Pharma Strike $120M Deal for Narcolepsy